In a recent article published in the Archives of Dermatological Research, Synovea® HR (INCI: Hexylresorcinol) and hydroquinone are the focus of a double-blind study to determine their effectiveness for remedying dyspigmentation.
Dyspigmentation is an abnormality in the pigmentation of the skin that’s a common concern in dermatology. In the United States, a popular topical medication for dyspigmentation is hydroquinone, a synthetic compound that reduces melanin production to help lighten dark spots and other forms of hyperpigmentation.
The problem with hydroquinone is its potential safety issues:
- Cytotoxicity to melanocytes
- Systemic absorption
- Metabolism in distant organs
- The production of potentially carcinogenic metabolites
- Skin rashes, facial swelling and ochronosis (discoloration of the skin)
Because of these concerns, dermatologists/researchers considered Synovea® HR a possible alternative due to its skin-lightening and even toning properties. The dermatologists/researchers performed a double-blind randomized split-body study to compare how topical Synovea® HR and hydroquinone affected the skin tone and pigmentation on the face and hands.
The study included 32 healthy female participants between 35-65 years old who received either topical 1% Synovea® HR or topical 2% hydroquinone. The topical preparation was applied to either the left or right side of the face and the corresponding hand over a 12-week period. The results found that pigmentation was significantly reduced at 4 and 12 weeks with no difference between groups and no adverse effects.
In conclusion, 1% of Synovea® HR in a topical application is a well-tolerated ingredient that’s equal to 2% hydroquinone in reducing facial and hand dyspigmentation.
To access the article, click here.
